Solid Biosciences stock draws fresh Buy rating from J.P. Morgan

Solid Biosciences stock drew fresh analyst support on Thursday, November 12, 2026, after J.P. Morgan analyst Anupam Rama maintained a Buy rating and set an USD 11.00 price target. The assessment was reported by Markets Insider, citing TipRanks.

Analyst view meets pipeline milestones

Rama's rating followed Solid Biosciences' latest quarterly update for the period ended September 30. The company reported a GAAP net loss of USD 53.95 million for the quarter, compared with a loss of USD 45.78 million in the same period a year earlier, according to the report.

William Blair initiated coverage on November 9 with a Buy-equivalent Outperform rating and an USD 11.00 price target, adding to the recent analyst attention around Solid's clinical pipeline. Ratings and targets remain research views rather than operating results, and their relevance depends on clinical and regulatory execution.

Next scheduled investor event

Solid Biosciences plans to participate in the 2026 Jefferies Global Healthcare Conference in London on Monday, November 16. President and Chief Executive Officer Bo Cumbo is scheduled for a fireside chat at 2:30 p.m. GMT, or 9:30 a.m. Eastern Time. The company announced the event on November 10 in a release carried by GlobeNewswire.

Rare-disease gene therapy focus

Solid Biosciences is a Charlestown, Massachusetts-based precision genetic medicine company developing gene therapy candidates for rare neuromuscular and cardiac diseases. Its programs address Duchenne muscular dystrophy, Friedreich's ataxia and several inherited cardiac conditions, while the company also develops delivery and genetic-regulator technologies. The business remains a specialized clinical-stage developer focused on advancing a portfolio of candidates rather than a broad commercial drug portfolio.

The broader US market context is available through current S&P 500 market reports.

More news and analyses on Solid Biosciences stock